Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.

Front Oncol · 2021 · PMC8787090 · PMID 35087749

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Results of TNBC patients in DFS still showed a trend to favor nab-paclitaxel (83.30% vs 72.70%), but no statistical significance was found.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.